Brief: Oragenics Entered Sales Agreement With Agent
24/02/2023 23:18
Feb 24 (Reuters) - Oragenics Inc OGEN.A :
* ORAGENICS INC - ENTERED SALES AGREEMENT WITH AGENT,
PURSUANT TO
WHICH CO MAY ISSUE, SELL, FROM TIME TO TIME, SHARES OF ITS
COMMON STOCK
* ORAGENICS INC - TO USE NET PROCEEDS FROM OFFERING TO
CONTINUE
FUNDING ITS PRE-CLINICAL DEVELOPMENT OF ITS SARS-COV-2 VACCINE &
LANTIBIOTICS PROGRAM
* ORAGENICS INC - PROSPECTUS SUPPLEMENT FILED WITH SEC ON
FEBRUARY
24, 2023 IS ONLY OFFERING SHARES HAVING AN AGGREGATE OFFERING
PRICE OF $5 MILLION
Source text for Eikon: ID:
Further company coverage: OGEN.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oragenics
See all newsBrief: Oragenics Reports Continued Clinical Progress, Provides Regulatory And NYSE American Listing Update
Brief: Oragenics Signs Letter Of Intent To License Cardiodialysis™ Technology From Sigyn Therapeutics To Target Tbi-Induced Systemic Inflammation
Brief: Oragenics Inc - Signs Letter Of Intent To License Cardiodialysis From Sigyn Therapeutics - SEC Filing
Brief: Oragenics Activates Second Site In Phase Iia Clinical Trial Of Onp-002 For Concussion And Mild Traumatic Brain Injury.
Brief: Oragenics Enters Settlement Agreement With Ladenburg Thalmann - Sec Filing